Chen C-M, Chang J W-C, Cheung Y-C, Lin G, Hsieh J-J, Hsu T, Huang S-F
Department of Imaging and Intervention, and Department of Hematology and Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Acta Radiol. 2008 Nov;49(9):991-4. doi: 10.1080/02841850802294410.
Target therapy with a new class of epidermal growth factor receptor (EGFR) inhibitors shows improved clinical response in EGFR gene-mutated lung cancers.
To evaluate the use of computed tomography (CT)-guided core-needle biopsy specimens for the assessment of EGFR gene mutation in non-small-cell lung cancer (NSCLC).
Seventeen (nine males, eight females) patients with advanced NSCLC were enrolled in this study. All patients underwent CT-guided core-needle biopsy of the lung tumor prior to treatment with the EGFR inhibitor gefitinib. There were no life-threatening complications of biopsy. The specimens were sent fresh-frozen for EGFR mutation analysis and histopathological study.
There were 12 (70.6%) EGFR gene mutants and five (29.4%) nonmutants. The objective response rate to gefitinib therapy was 73.3% (11 of 15 patients), with 91.7% (11 of 12 mutants) for the mutant group and 0% for the nonmutant group.
CT-guided core-needle biopsy of advanced NSCLC enables the acquisition of sufficient tissue for EGFR gene mutation analysis.
使用新型表皮生长因子受体（EGFR）抑制剂进行的靶向治疗在EGFR基因突变的肺癌中显示出更好的临床反应。
评估计算机断层扫描（CT）引导下的粗针活检标本在非小细胞肺癌（NSCLC）EGFR基因突变评估中的应用。
17例（9例男性，8例女性）晚期NSCLC患者纳入本研究。所有患者在接受EGFR抑制剂吉非替尼治疗前均接受了CT引导下的肺肿瘤粗针活检。活检无危及生命的并发症。标本新鲜冷冻后进行EGFR突变分析和组织病理学研究。
有12例（70.6%）EGFR基因突变型和5例（29.4%）非突变型。吉非替尼治疗的客观缓解率为73.3%（15例患者中的11例），突变组为91.7%（12例突变型中的11例），非突变组为0%。
CT引导下对晚期NSCLC进行粗针活检能够获取足够的组织用于EGFR基因突变分析。
